# OnCo record nct04557059 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04557059/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04557059", "NCT04557059" ;
  schema:name "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer"@en ;
  schema:alternateName "PRIMORDIUM"@en ;
  schema:description "A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Pharmaceutica N.V., Belgium, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04557059/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04557059> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2020-11-12" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:drugs <https://onco.cc/drugs/apalutamide/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .